Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients

NCT01663116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis Aggravated

Interventions

GENETIC: Stem cells
GENETIC: Placebo

Sponsor

Tigenix S.A.U.